Webinars

Alzheimer’s Disease: The Role of Amyloid Beta 42/40 in Risk Assessment

Date: Wednesday, November 15, 2017

Author: Clarke, Nigel J., PhD
Senior Science Director for Mass Spectrometry and Automation
Quest Diagnostics Nichols Institute
San Juan Capistrano, CA

  
Also by this Author 

Category: For Credit, Webinar

Description: Dr. Clarke discusses new innovations in AD biomarker-assay development and utilization, driven by the use of tandem mass spectrometry in lieu of previously used ELISA methods, compares the clinical impact of having a Aβ 42/40 ratio vs traditional biomarker assays and describes the clinical utility of testing Aβ 42/40 cerebrospinal fluid ratios, and using an overall risk assessment score, to support the differential diagnosis of patients with mild cognitive impairment.

At the conclusion of this program, participants will be able to:
• Discuss new innovations in AD biomarker-assay development and utilization, driven by the use of tandem mass spectrometry in lieu of previously used ELISA methods
• Compare the clinical impact of having an Aβ42/40 ratio vs traditional biomarker assays
• Describe the clinical utility of testing Aβ42/40 cerebrospinal fluid ratios, and using an overall risk assessment score, to support the differential diagnosis of patients with mild cognitive impairment (MCI)

ASCLS P.A.C.E.® credits are available to laboratory professionals through May 9, 2018.